Other
Pyrotinib
0
Pipeline Programs↗
1
Active Trials↗
0
Companies Involved↗
Pyrotinib is an early-stage landscape with 0 programs across 0 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
8
clinical trials
Completed5 · 63%
Unknown status2 · 25%
Recruiting1 · 13%
Clinical Trials
Trial Activity
8 trials
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Completed·—·N/A·NCT04756921·30 enrolled
Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04063462·60 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)